scholarly journals Predictors of patient cognitive therapy skills and symptom change in two randomized clinical trials: The role of therapist adherence and the therapeutic alliance.

2012 ◽  
Vol 80 (3) ◽  
pp. 373-381 ◽  
Author(s):  
Christian A. Webb ◽  
Robert J. DeRubeis ◽  
Sona Dimidjian ◽  
Steven D. Hollon ◽  
Jay D. Amsterdam ◽  
...  
Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 976
Author(s):  
Fiorenzo Moscatelli ◽  
Francesco Sessa ◽  
Anna Valenzano ◽  
Rita Polito ◽  
Vincenzo Monda ◽  
...  

At the end of 2019, a new coronavirus (COVID-19) appeared on the world scene, which mainly affects the respiratory system, causing pneumonia and multi-organ failure, and, although it starts with common symptoms such as shortness of breath and fever, in about 2–3% of cases it leads to death. Unfortunately, to date, no specific treatments have been found for the cure of this virus and, therefore, it is advisable to implement all possible strategies in order to prevent infection. In this context, it is important to better define the role of all behaviors, in particular nutrition, in order to establish whether these can both prevent infection and improve the outcome of the disease in patients with COVID-19. In the literature, it is widely shown that states of malnutrition, overweight, and obesity negatively affect the immune system, leading to viral infections, and several studies have shown that nutritional interventions can act as immunostimulators, helping to prevent viral infections. Even if several measures, such as the assumption of a specific diet regimen, the use of dietary supplements, and other similar interventions, are promising for the prevention, management, and recovery of COVID-19 patients, it is important to highlight that strong data from randomized clinical trials are needed to support any such assumption. Considering this particular scenario, we present a literature review addressing several important aspects related to diet and SARS-CoV-2 infection, in order to highlight the importance of diet and supplementation in prevention and management of, as well as recovery from COVID-19.


2021 ◽  
Author(s):  
Maliha Ibrahim ◽  
Suzanne Levy ◽  
Bob Gallop ◽  
Stephanie Krauthamer Ewing ◽  
Aaron Hogue ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (5) ◽  
pp. e96905 ◽  
Author(s):  
Giuseppe Grosso ◽  
Andrzej Pajak ◽  
Stefano Marventano ◽  
Sabrina Castellano ◽  
Fabio Galvano ◽  
...  

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14557-e14557
Author(s):  
Fabrizio Drudi ◽  
Emiliano Tamburini ◽  
Manuela Fantini ◽  
Antonio Polselli ◽  
Lucia Stocchi ◽  
...  

Psychotherapy ◽  
1999 ◽  
Vol 36 (4) ◽  
pp. 320-328 ◽  
Author(s):  
Neil A. Rector ◽  
David C. Zuroff ◽  
Zindel V. Segal

Oncotarget ◽  
2017 ◽  
Vol 8 (42) ◽  
pp. 72950-72958 ◽  
Author(s):  
Yun Liu ◽  
Guoxin Ye ◽  
Dali Yan ◽  
Lei Zhang ◽  
Fan Fan ◽  
...  

2021 ◽  
Vol 5 (3) ◽  
pp. 395-400
Author(s):  
Emilia ◽  
Zulkhair Ali

A B S T R A C TAnemia contributes to increased morbidity and mortality in chronic kidney diseasepatients. The pathogenesis of anemia in these patients is multifactorial, but thecontribution of erythropoietin deficiency becomes greater as glomerular filtrationrate declines which related to decreased nephron mass. The current standard ofcare includes supplemental iron, erythropoiesis-stimulating agents (ESA), and redblood cell transfusions, although each has drawbacks. Lately, concern has arisenfollowing randomized clinical trials showing that higher hemoglobin targets and/orhigh ESA doses may cause significant harm including increasing cardiovascular andthrombotic events, and even death. Recent experimental and clinical studies showthe promising efficacy of hypoxia inducible factor (HIF) stabilizer which stimulatesendogenous erythropoietin production and enhance iron availability.


2019 ◽  
Vol 15 (2) ◽  
pp. 1-17
Author(s):  
Scott D Gelfand

In this essay, I suggest that a slightly modified version of Freedman’s formulation of the clinical equipoise requirement is justified. I begin this essay with a brief discussion of the equipoise requirement. In the second and third sections, I discuss several objections to the clinical equipoise requirement as well as two attempts to justify the equipoise requirement. In the fourth section, in order to gain some insight into what it means to say that a physician has an obligation to act in the best interest of her patient, I examine a similar obligation, namely, a parent’s obligation to act in her child’s best interest. I claim that there are several uncontroversial exceptions to this obligation, and these exceptions arise when a parent occupies a role more complex than the role of parent simpliciter. In the fifth section, I explore whether the exceptions to a parent’s obligation to act in her child’s best interest may shed light on some exceptions to a physician–researcher’s obligation to act in the best interest of her patient. These exceptions, I suggest, arise when a physician occupies a role more complex than physician simpliciter, and they ground a permission to conduct randomized clinical trials, even if doing so is not in the best interest of a physician–researcher’s patients. I furthermore claim that these exceptions provide justification for a modified formulation of the clinical equipoise requirement.


Sign in / Sign up

Export Citation Format

Share Document